January 14, 2025 Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio Read More November 12, 2024 Ventyx Biosciences to Participate in Three Upcoming Investor Conferences Read More November 7, 2024 Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress Read More October 15, 2024 Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 Read More September 23, 2024 Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi Read More September 6, 2024 Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease Read More August 30, 2024 Ventyx Biosciences Announces Departure of Chief Financial Officer Read More August 28, 2024 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read More August 8, 2024 Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress Read More July 29, 2024 Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Participants with Moderately to Severely Active Crohn’s Disease Read More
